{
  "docId": "019de073-ed1e-723c-a28e-3c378280574e",
  "docSlug": "3439c61eec2c1805f58a361a1d0fbc84",
  "documentTitle": "ATAI | Investor Presentation Deck | 36 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 36,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes a quote from Keith Nuechterlein and a detailed clinical trial timeline.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ed1e-723c-a28e-3c378280574e/22",
  "deckHref": "/decks/019de073-ed1e-723c-a28e-3c378280574e",
  "deckJsonHref": "/decks/019de073-ed1e-723c-a28e-3c378280574e.json",
  "deckAnchorHref": "/decks/019de073-ed1e-723c-a28e-3c378280574e#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.6,
        "x": 0.371,
        "y": 0.27
      },
      "kind": "chart",
      "text": "T-Scores for HVLT, Symbol Coding, and Category Fluency across 10mg, 20mg, 40mg, 80mg doses",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04583488-3676-42fa-bfb2-ce0ea6123caf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.371,
        "y": 0.68
      },
      "kind": "diagram",
      "text": "Completed Phase 2 PoM Trial timeline showing cohorts, dosing, and endpoints",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07680a7c-2953-4e36-8a1a-303e5c154c62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.371,
        "y": 0.11
      },
      "kind": "quote",
      "text": "Symbol coding response is at a level that would correlate with better work/school performance",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c149910-a424-4ca9-ad39-0c842248e645",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.371,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: CIAS = Cognitive impairment associated with schizophrenia; RL-007 is (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salt; TID denotes 3x/day dosing",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67c33b59-7da5-487d-a145-4947cd13c924",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.34,
        "x": 0.015,
        "y": 0.16
      },
      "kind": "table",
      "text": "Ownership: 51.9%, Product: RL-007, Pharmacology: Cholinergic/Glutamatergic/GABA-B, Features: No SAEs, Indications: CIAS/Autism/Alzheimer's, Status: Phase 2a complete, IP: Issued patents, Highlight: Phase 2 in 180 patients",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf5160c0-ceb9-4bea-89bb-44cd287627c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.371,
        "y": 0.035
      },
      "kind": "title",
      "text": "RL-007 has previously shown pro-cognitive effects in human clinical studies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "897c7eec-93d7-4fa4-a49f-6af338cdfbe5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "executive-summary",
      "slug": null,
      "matchId": "4c8638a9-34ab-4f40-9e77-537132ff64e5",
      "evidence": "Structured summary of product, pharmacology, status, and clinical data.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}